Company Overview
Company Type: Public Company
Website: www.ibex.ca
Number of Employees: 17
Ticker: IBT (TSXV)
Year Founded: 1972


Business Description
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
7.8
Market Capitalization
24.0
TEV/Total Revenue
2.3x
EBITDA
2.1
Total Enterprise Value
18.0
TEV/EBITDA
7.6x
EBIT
2.0
Cash & ST Invst.
7.5
P/Diluted EPS Before Extra
16.1x
Net Income
1.7
Total Debt
1.5
Price/Tang BV
2.1x
Capital Expenditure
(0.7)
Total Assets
14.1
Total Debt/EBITDA
0.6x
Currency in CAD in mm, LTM as of Apr-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023


Guidance Snapshot (Current Fiscal Year End: Jul-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
Revenue (mm)
-
-
-
7.89 - -
-






Key Professionals
Name
Title
Baehr, Paul 
President, CEO & Chairman
Franco, Belinda 
CFO, VP of Finance & Administration and Secretary
Pallapothu, Mahendra Kumar
Vice President of Operations

Key Board Members
Name
Title
Baehr, Paul 
President, CEO & Chairman
DeLuccia, Robert J.
Independent Lead Director
Netto, Danilo 
Independent Director
Zimmermann, Joseph 
Independent Director
Charette, Christine 
Independent Director
Connop, Bruce P.
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
5485 Rue Pare Suite 100 | Montreal, QC | H4P 1P7 | Canada
Fax: 514 344 8827

Current and Pending Investors
Milfam LLC

Prior Investors
CDP Capital-Technology Ventures, Clairvest Equity Partners II, L.P, Clairvest Group Inc. (TSX:CVG), GrowthWorks Canadian Fund Ltd., L.P.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.96
Market Cap (mm)
24.0
Open
 1.00
Shares Out. (mm)
24.8
Previous Close
 0.97
Float %
71.7%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(1.0)%
Dividend Yield %
-
Day High/Low
 1.00/ 0.96
Diluted EPS Excl. Extra Items
0.06
52 wk High/Low
 1.20/ 0.48
P/Diluted EPS Before Extra
16.09x
Volume (mm)
0.03
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
0.01


 
Delayed Quote** | Last Updated on Oct-11-2023 01:54 PM (GMT-5)
TSXV:IBT - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Bio-Research Products, Inc.
Bio-Research Products, Inc. specializes in the manufacture of enzymes for biomedical manufacturing and research applications. The company’s products include wheat germ lectin (agglutinin), concanavalin A, aminoethylbenzene sulfonyl flouride HCl, and diamine oxidase. Its services include protein purification, characterization, and analysis; diagnostic reagent components; custom enzyme production; and contract manufacturing of raw material enzymes for diagnostics, pharmaceutical, and industrial applications. The company was founded in 1975 and is based in North Liberty, Iowa. As of December 31, 2012, Bio-Research Products, Inc. operates as a subsidiary of IBEX Technologies Inc.

United States and Canada
Biotechnology
2.00
2.00
0.00
IBEX Pharmaceuticals Inc.
IBEX Pharmaceuticals Inc. is a biotechnology company. It is based in Montreal, Canada.

United States and Canada
Biotechnology
5.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-17-2023
-
Buyback
Target
IBEX Technologies Inc. (TSXV:IBT)


-
Aug-02-2022
-
Buyback
Target
IBEX Technologies Inc. (TSXV:IBT)


0.01
Jan-2-2013
Dec-31-2012
Merger/Acquisition
Buyer
Bio-Research Products, Inc.
IBEX Technologies Inc. (TSXV:IBT)

2.70
Jan-30-2007
Cancelled
Merger/Acquisition
Buyer
Garvinci Inc.
IBEX Technologies Inc. (TSXV:IBT)

3.70
Nov-2-2004
Cancelled
Merger/Acquisition
Target
IBEX Technologies Inc. (TSXV:IBT)
PreMD Inc.

7.26
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-04-2023
Buyback Transaction Closings
IBEX Technologies Inc.'s Equity Buyback announced on August 2, 2022, has expired.
Jul-17-2023
Buyback Transaction Announcements
IBEX Technologies Inc. (TSXV:IBT) announces an Equity Buyback for 1,500,000 shares, representing 6.06% of its issued share capital.
Jul-17-2023
Buyback Transaction Announcements
IBEX Technologies Inc. authorizes a Buyback Plan.
Jun-07-2023
Buyback Tranche Update
Tranche Update on IBEX Technologies Inc. (TSXV:IBT)'s Equity Buyback Plan announced on August 2, 2022.
Mar-20-2023
Buyback Tranche Update
Tranche Update on IBEX Technologies Inc. (TSXV:IBT)'s Equity Buyback Plan announced on August 2, 2022.

M&A Advisors
BMO Nesbitt Burns Inc., Heenan Blaikie LLP


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
BMO Nesbitt Burns Inc., Heenan Blaikie LLP
Private Placement Advisors
Versant Partners Inc.


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Oct 10, 2023 12:29 AM
IBT
IBEX Technologies Inc (IBT.CVE) - Financial Analysis Review
Reports
168
S&P Global Compustat

Oct 05, 2023 03:18 AM
IBT
IBEX Technologies Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 06:19 AM
IBT
ValuEngine - Toronto Quantitative Stock Report for IBT
Reports
5
CFRA Equity Research

Oct 01, 2023 02:12 PM
IBT
IBEX Technologies Inc.
Reports
9
MarketLine

Sep 30, 2023 06:01 AM
IBT
IBEX Technologies Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
16
MarketLine

Sep 20, 2023 06:01 AM
IBT
IBEX Technologies Inc.
Reports
23
GlobalData

Sep 13, 2023 03:27 AM
IBT
IBEX Technologies Inc (IBT.CVE) - Financial Analysis Review
Reports
168
S&P Global Compustat

Sep 07, 2023 02:59 AM
IBT
IBEX Technologies Inc 2023_09_07
Reports
14
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Aug 15, 2023 06:00 PM
IBT
Will IBEX Technologies Inc Deliver Long-Term Returns?
Ratings Change*
12
S&P Global Compustat

Jul 06, 2023 02:41 AM
IBT
IBEX Technologies Inc 2023_07_06
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


McLean Capital Inc.

2,969,800

11.98

2.9

May-31-2023


Milfam LLC

2,572,350

10.38

2.5

Dec-13-2022


Baehr, Paul 

2,456,477

9.91

2.4

Dec-03-2022


Subin, Neil S.

1,506,850

6.08

1.5

Dec-13-2022


DeLuccia, Robert J.

68,000

0.27

0.1

Dec-03-2022


Netto, Danilo 

21,500

0.09

0.0

Dec-03-2022



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
McLean Capital Inc.
2,969,800
2,969,800

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Arthritis Assays, Arthritis Diagnostic Kits, Chondroitinase AC, Chondroitinase B, CP II ELISA Assay, Enzymes, Lyophilization Services, Urine C2C ELISA


Upcoming Events
Date/Time
Type
Nov-08-2023
Estimated Earnings Release Date (S&P Global Derived)
Dec-15-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Jul-17-2023
-
IBEX Technologies Inc. (TSXV:IBT)
SEDAR
News Releases
20 KB
Jun-07-2023
-
IBEX Technologies Inc. (TSXV:IBT)
SEDAR
Securities Acquisition Filings
258 KB
Jun-07-2023
-
IBEX Technologies Inc. (TSXV:IBT)
SEDAR
Securities Acquisition Filings
209 KB
Jun-07-2023
-
IBEX Technologies Inc. (TSXV:IBT)
SEDAR
News Releases
48 KB
Jun-07-2023
Apr-30-2023
IBEX Technologies Inc. (TSXV:IBT)
SEDAR
Interim Financial Statements
554 KB
Mar-20-2023
-
IBEX Technologies Inc. (TSXV:IBT)
SEDAR
News Releases
57 KB
Mar-20-2023
Jan-31-2023
IBEX Technologies Inc. (TSXV:IBT)
SEDAR
Interim Financial Statements
561 KB
Jan-24-2023
-
IBEX Technologies Inc. (TSXV:IBT)
SEDAR
Management Proxy Materials
76 KB
Jan-24-2023
-
IBEX Technologies Inc. (TSXV:IBT)
SEDAR
Management Proxy Materials
76 KB
Dec-20-2022
-
IBEX Technologies Inc. (TSXV:IBT)
SEDAR
Management Proxy Materials
76 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Subin, Neil S.
Oct-08-2020
Common Shares
1,506,850
0
Other Acquisition
New
Exchange Announcement
-
Oct-08-2020
Common Shares
753,425
0
Other Acquisition
-
Exchange Announcement
-
Oct-08-2020
Common Shares
753,425
0
Other Acquisition
-
Exchange Announcement
Estate of Lloyd I Miller III
Oct-08-2020
Common Shares
(1,506,850)
0
Other Disposition
(100.00)
Exchange Announcement
Baehr, Paul  (President, CEO & Chairman)
Apr-10-2018
Common Shares
1,600,000
379,826
Open Market Acquisition
186.81
Exchange Announcement
-
Apr-10-2018
Common Shares
1,572,500
372,777
Open Market Acquisition
-
Exchange Announcement
-
Apr-10-2018
Common Shares
27,500
7,050
Open Market Acquisition
-
Exchange Announcement
Baehr, Paul  (President, CEO & Chairman)
Apr-10-2018
Common Shares
(1,600,000)
(379,296)
Open Market Disposition
(39.44)
Exchange Announcement
Poulin, Catherine  (Former Vice President of Production)
Mar-20-2018
Common Shares
50,000
5,197
Derivative Exercise and Retained Stock
(100.00)
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Baehr, Paul 
President, CEO & Chairman
514-344-4004 x 143
514 344 8827
pbaehr@ibex.ca
DeLuccia, Robert J.
Independent Lead Director
(914) 949-3898
514 344 8827
rjdeluccia@optonline.net
Netto, Danilo 
Independent Director
-
514 344 8827

Zimmermann, Joseph 
Independent Director
-
514 344 8827

Charette, Christine 
Independent Director
-
514 344 8827

Connop, Bruce P.
Independent Director
-
514 344 8827

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Baehr, Paul 
President, CEO & Chairman
514-344-4004 x 143
514 344 8827
pbaehr@ibex.ca
Franco, Belinda 
CFO, VP of Finance & Administration and Secretary
(514) 344-4004
514 344 8827

Pallapothu, Mahendra Kumar
Vice President of Operations
-
514 344 8827

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
